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OBJECTIVE—To establish the role of the transcription factor
Pax4 in pancreatic islet expansion and survival in response to
physiological stress and its impact on glucose metabolism, we
generated transgenic mice conditionally and selectively over-
expressing Pax4 or a diabetes-linked mutant variant (Pax4R129W)
in b-cells.
RESEARCH DESIGN AND METHODS—Glucose homeostasis
and b-cell death and proliferation were assessed in Pax4- or
Pax4R129W-overexpressing transgenic animals challenged with
or without streptozotocin. Isolated transgenic islets were also
exposed to cytokines, and apoptosis was evaluated by DNA frag-
mentation or cytochrome C release. The expression proﬁles of
proliferation and apoptotic genes and b-cell markers were stud-
ied by immunohistochemistry and quantitative RT-PCR.
RESULTS—Pax4 but not Pax4R129W protected animals against
streptozotocin-induced hyperglycemia and isolated islets from
cytokine-mediated b-cell apoptosis. Cytochrome C release was
abrogated in Pax4 islets treated with cytokines. Interleukin-1b
transcript levels were suppressed in Pax4 islets, whereas they
were increased along with NOS2 in Pax4R129W islets. Bcl-2,
Cdk4, and c-myc expression levels were increased in Pax4 islets
while MafA, insulin, and GLUT2 transcript levels were sup-
pressed in both animal models. Long-term Pax4 expression pro-
moted proliferation of a Pdx1-positive cell subpopulation while
impeding insulin secretion. Suppression of Pax4 rescued this de-
fect with a concomitant increase in pancreatic insulin content.
CONCLUSIONS—Pax4 protects adult islets from stress-induced
apoptosis by suppressing selective nuclear factor-kB target genes
while increasing Bcl-2 levels. Furthermore, it promotes dediffer-
entiation and proliferation of b-cells through MafA repression,
with a concomitant increase in Cdk4 and c-myc expression.
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D
iabetes is a disease characterized by high levels
of circulating blood glucose. The etiology
involves insufﬁcient release of insulin from
pancreatic islet b-cells and resistance of target
tissues to the action of the hormone. The two most
common forms of diabetes are type 1 diabetes characterized
by a destruction of b-cells (1) and type 2 diabetes typiﬁed by
b-cell failure combined with insulin resistance (2). Factors
such as the environment and genetic predisposition are key
determinants that inﬂuence development and progression
of the disease. Genetic studies including linkage analysis,
candidate gene approaches, and more recently, genome-
wide association studies (GWAS) have identiﬁed at least 40
loci affecting risk of type 1 diabetes and 27 type 2 diabetes
susceptibility genes (3–5). Although GWAS have been a
powerful approach to yield new diabetogenes, susceptible
gene loci for which functions may be altered by environ-
mental factors such as pregnancy and obesity remain to be
identiﬁed.
One such susceptibility gene locus not highlighted by
GWAS encodes the islet b-cell transcription factor Pax4.
Expression of the pax4 gene is mandatory for the de-
velopment and maturation of b-cells (6). Although de-
tectable, Pax4 expression was found to be low in adult
b-cells (7). Forced expression of Pax4 in embryonic
a-cells induced a complete phenotypic change toward
b-cells indicating that Pax4 is a master regulator of the
b-cell genetic program (8).
Mutations and polymorphisms in the pax4 gene have
been associated with both type 1 and type 2 diabetes in
several populations, contrasting with other diabetogenes
for which association has only been linked to one or the
other form of diabetes (7,9). Interestingly, we found that
Pax4 expression is increased in type 2 diabetic islets, an
effect that is most likely mediated by high blood glucose
levels (10). Together, these studies suggest that Pax4 may
function as a survival and/or proliferation gene allowing
mature islets to adapt in response to physiological cues.
Consistent with this premise, Pax4 mRNA levels were in-
creased in islets cultured in the presence of glucose,
betacellulin, activin A, and glucagon-like peptide-1 (10).
Ectopic expression of mouse Pax4 in human or rat islets
and in the mouse MIN6 cell line conferred protection
against cytokine-mediated cell death and promoted repli-
cation (11,12). A diabetes-linked mutant variant R121W,
identiﬁed in the Japanese population (13,14), was less ef-
ﬁcient in protecting human islets against cytokines (11).
Although these in vitro studies suggest a fundamental
role of Pax4 in b-cell survival and replication, the impact of
Pax4 in vivo and its relation to diabetes remains to be
established. Herein, we have generated two transgenic
mouse lines that conditionally express Pax4 or its mutant
variant R121W (PAX4R129W in mice) in b-cells. Our
results demonstrate that conditional overexpression of
Pax4 in adult b-cells protects transgenic animals against
streptozotocin (STZ)-induced hyperglycemia and isolated
islets against cytokines, while animals expressing the mu-
tant variant were susceptible to developing hyperglycemia
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ORIGINAL ARTICLEand b-cell death by both treatments. Long-term expression
of Pax4 in animals repressed MafA and insulin, resulting in
blunted glucose-induced insulin secretion suggesting de-
differentiation of b-cells.
RESEARCH DESIGN AND METHODS
Transgenic animals. The pIRES2-DsRedexpress (Clontech) vector was used
for the generation of the inducible Pax4 or the mutant variant Pax4R129W
cDNA cassette. The ﬁnal construct contained the tetracycline responsive
promoter, the rabbit b-globin intron followed by the Pax4 or Pax4R129W
coding sequence. A myc-epitope and polyhistidine tag were added for de-
tection purposes. DsRedexpress was included in the constructs in order to
follow Pax4 induction using noninvasive in vivo imaging. Pax transgenic ani-
mals were crossed to RIPrtTA mice to generate double transgenic descen-
dants with conditional expression of Pax4 or Pax4R129W speciﬁcally in b-cells.
Induction of transgene expression was achieved by providing 1 g/L of doxy-
cycline (Sigma-Aldrich) in the drinking water. The GLUT2 knockout mouse
has been described elsewhere (15). The Geneva Veterinary Cantonal Ofﬁce
and the CABIMER animal committee approved all experiments.
Glucose and insulin measurements. Animals fasted overnight or for 4 h and
were injected intraperitoneally with 2 g glucose/kg body wt or with 1 unit
insulin/kg body wt Actrapid (Novo Nordisk Pharma). Blood was collected from
tail vein, and glucose levels were measured with a Precision Xceed glucometer.
Plasma insulin levels were measured at 0 and 15 min using a mouse insulin
ELISA kit (Mercodia, Uppsala, Sweden). Pancreatic insulin content was de-
termined using an insulin enzyme immunoassay kit (SPI-BIO; Bertin Pharma
Biotech Division, Brunschwig, Basel, Switzerland).
STZ treatment. STZ was prepared in 0.1 mmol/L sodium citrate at pH 4.5 and
administered by intraperitoneal injection (200 mg/kg body wt). Blood glucose
was determined before STZ injection and then three times per week.
Mouse islet isolation. Pancreatic islets were isolated by collagenase (Roche,
Switzerland) digestion, handpickedand maintainedin 11.1 mmol/Lglucose/RPMI-
1640 (Invitrogen, Switzerland) supplemented with 10% FCS (Brunschwig), 100
units/mL penicillin, and 100 mg/mL streptomycin (Sigma, St-Gallen, Switzerland).
Quantitative real time PCR. Total RNA from islets was extracted using the
RNeasy Micro Kit (Qiagen), and quantitative real time PCRs (Q-RT-PCRs) were
performed as previously described (16). Primer sequences were designed us-
ing the Primer Express Software (Applera Europe) and can be obtained upon
request.
Transfection studies. Transient transfections were performed as previously
described (11). The luciferase reporter contructs, pFOX-Luc and pFOX-MafAR3-Luc
(region 3 of the MafA promoter specifying b-cell expression), were provided by
Dr. R. Stein (Vanderbilt University, Nashville, TN).
Cytokine treatment, apoptosis, and nitrite measurements. Islets were
isolatedfromtransgenicanimalsthathadreceived1g/Ldoxycyclineindrinking
water for 1 month. Islets were cultured for 48 h in the presence of 1 ug/L
doxycycline prior to the addition of 0.25 ng/mL interleukin (IL)-1b, 9.1 ng/mL
tumor necrosis factor-a, and 100 ng/mL g-interferon (R&D Systems). Apo-
ptosis was evaluated 24 h posttreatment using the Cell Death ELISA Plus kit
(Roche). Alternatively, cell death was estimated by cytochrome C release. Dis-
persed islets were concentrated by cytospin onto glass slides, and immuno-
ﬂuorescence was performed using anticytochrome C serum (BD Biosciences)
and antiserum for the mitochondrial marker TOM 20 (Santa Cruz). Nitrite pro-
duction in culture media was determined using the Griess reaction (Sigma).
Proliferation assay. Mice were injected with 1 mL BrdU solution/100 g body
wt (Roche); 24 h later, they were killed. Proliferation was detected by im-
munohistochemistry on pancreatic sections.
Immunohistochemistry. For parafﬁn sections, pancreata were dissected and
ﬁxed in 4% paraformaldehyde. Dehydration, embedding, and sectioning were
performedat either the Geneva or CABIMER Histology platform. Sections were
rehydrated in ethanol and blocked in PBS containing 1% BSA and 0.1% Tween.
The following primary polyclonal antibodies were used: guinea pig anti-insulin,
mouse anti-glucagon, rabbit anti-pdx1 (1:200; provided by C. Wright, Vanderbilt
University), rabbit anti-GLUT2 (1:200), and rabbit anti-MafA (1:200; Bethyl). A
mouse monoclonal BrdU was also used. The following secondary antibodies
were added: Alexa Fluor 568 goat anti-guinea pig, Alexa Fluor 488 goat anti-
mouse, and Alexa Fluor 488 goat anti-rabbit. For cryostat sections, pancreata
were frozen in liquid nitrogen prior to sectioning and mounting. Sections were
ﬁxed in 4% paraformaldehyde, and immunodetections were performed with the
following primary polyclonal antibodies: rabbit anti-Pax4 (provided by Dr. Sosa-
Pineda) and guinea pig anti-insulin. Secondary antibodies used were as follows:
Alexa Fluor 568 goat anti-rabbit and Alexa Fluor 488 goat anti–guinea pig.
Immunoblot analysis. Islets were harvested in lysis buffer (0.05 mol/L TRIS-
HCl,pH7.5,and62.5mmol/LEDTA),cellsdisruptedbysonication,andproteins
resolvedby10%PAGE.Gelswereprocessedforimmunoblottingusingstandard
procedures.Thefollowingprimarypolyclonalantibodieswereused:rabbitanti-
Pax4, goat DsRed (Santa Cruz), and rabbit TFIIE-a (Santa Cruz). A goat anti-
rabbit IgG antiserum conjugated to horseradish peroxidase (GE Healthcare)
was then added, and immunoreactive products were visualized by chemi-
luminescence (Pierce, Rockford, IL).
Statistical analysis. Results are expressed as means 6 SEM. Statistical dif-
ferences were estimated using the unpaired t test, ANOVA with Bonferroni
post hoc test, or nonparametric Mann-Whitney test.
RESULTS
Pax4 overexpression in adult pancreatic b-cells does
not impact glucose homeostasis. To study in vivo the role
of Pax4 and the impact of a mutant variant associated with
diabetes in b-cell plasticity, we generated inducible double
transgenic mouse lines expressing RIP-rtTA along with either
Pax4/DsRedexpress or Pax4R129W/DsRedexpress. For sim-
plicity, double transgenic rtTA/Pax4 and rtTA/Pax4R129W
animals are denoted as Pax4 and Pax4R129W, respec-
tively, while control animals comprising single transgenic
littermates are referred to as ST. Q-RT-PCR revealed that
both Pax4 and Pax4R129W transcripts were expressed
to similar levels exclusively in islets of doxycycline-treated
transgenic Pax4 animals, whereas expression of the trans-
genes was not detected in either control ST mice or in double
transgenics that had not been provided with doxycycline
(Fig. 1A). Western blotting conﬁrmed expression of Pax4
and DsRedexpress in islets of the doxycycline-treated ani-
mals (Fig. 1B). Immunohistochemistry using either Pax4
or c-myc antisera further substantiated speciﬁce x p r e s s i o n
of Pax4 in islets and revealed colocalization with insulin in
most but not all b-cells, suggesting b-cell–restricted expres-
sion of the transgene (Fig. 1C and D).
In parallel, induction of DsRedexpress was monitored
by noninvasive in vivo imaging in Pax4 transgenic animals.
Fluorescence was detected in the abdominal region of
anesthetized living animals treated with doxycycline for 48 h
(Supplementary Fig. 1A). Imaging of extracted organs con-
ﬁrmed expression of DsRedexpress speciﬁcally in the pan-
creas of treated animals, while other organs exhibited
background ﬂuorescence (Supplementary Fig. 1B).
Pax4 transgenic animals that received doxycycline for 1
month exhibited normal glucose tolerance and insulin
sensitivity (Fig. 1E and F). Consistent with this ﬁnding,
glucose-induced insulin secretion was normal in islets
isolated from Pax4-expressing mice compared with control
ST islets (245 6 56 vs. 246 6 55 ng/mL). Similar results were
obtained with Pax4R129W animals (data not shown). These
results demonstrate that conditional expression of Pax4 can
be speciﬁcally achieved in islet b-cells and that its forced
expression does not alter glucose homeostasis in double
transgenic animals.
Overexpression of Pax4 but not Pax4R129W protects
mice against STZ-induced hyperglycemia. To assess
the protective role of Pax4 in vivo, doxycycline-treated
Pax4 or ST animals were challenged with a single high
dose of STZ to destroy b-cells. ST animals rapidly devel-
oped hyperglycemia while Pax4-overexpressing animals
remained normoglycemic throughout the experiment (Fig.
2A). For conﬁrmation that Pax4 was mediating the pro-
tection against STZ-induced hyperglycemia, doxycycline
was removed on day 27 and animals in group A received,
14 days later, a second STZ injection. Group A animals
developed hyperglycemia similar to that observed in ST
animals, whereas Pax4 animals that did not receive a sec-
ond STZ injection (group B) remained normoglycemic
(Fig. 2A). In an independent set of experiments, animals
continuously exposed to doxycycline and rechallenged
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glycemia, conﬁrming Pax4-dependent protection even af-
ter two high doses of STZ (Fig. 2B). Pax4R129W animals
challenged with a single dose of STZ developed an in-
termediate level of hyperglycemia, indicating that the
diabetes-associated mutant is less efﬁcient in protecting
mice against stress-induced hyperglycemia (Fig. 2C). Im-
munohistochemistry combined with morphometry analysis
revealed a clear reduction in insulin
+ cells, with a concom-
itant increase in glucagon
+ cells in STZ-injected ST animals
compared with what was observed in untreated mice
(Fig. 2D and Supplementary Fig. 2A and B). In contrast, islet
morphology and cell composition in Pax4-overexpressing
animals challenged with either one or two doses of STZ were
similar to those of islets from control animals (Fig. 2D and
Supplementary Fig. 2A and B). Islets from Pax4R129W mice
exhibited less insulin staining, suggesting a partial loss
of b-cells correlating with intermediate hyperglycemia
(Fig. 2D). These results show that overexpression of Pax4
protects b-cells against multiple STZ challenges and prevents
development of hyperglycemia, whereas the mutant is less
effective.
Pax4 but not Pax4R129W protects islets against
cytokine-induced apoptosis. For further assessment of
the protective action of Pax4, islets isolated from either
Pax4 or Pax4R129W transgenic animals were treated with
cytokines. Pax4 islets were protected against cytokine-
induced cell death compared with ST control animals that
displayed a threefold increase in cell death in the presence
of cytokines (Fig. 3A). Islets isolated from Pax4R129W
animals exhibited a similar degree of apoptosis compared
with cytokine-treated ST animals (Fig. 3A).
FIG. 1. Selective conditional overexpression of either Pax4 or Pax4R129W in mouse b-cells. A: Double transgenic animals bearing either the pTRE-
Pax4 or Pax4R129W-myc-His-IRES-DsRedexpress construct along with the RIP-rtTA transgene (denoted as Pax4 or Pax4R129W) were provided
with 1 g/L doxycycline (DOX) in drinking water for 1 month. Pax4 and Pax4R129W transcript levels were then evaluated by Q-RT-PCR. Relative
mRNA levels were normalized to the transcript levels of the housekeeping genes cyclophilin and/or rps29. Data were calculated as fold change
compared with ST animals. B: Doxycycline-induced Pax4 and DsRedexpress proteins were conﬁrmed by Western blot analysis. Immunoﬂuores-
cence analysis using antimyc (C) or anti-Pax4 (D) sera revealed speciﬁc expression of the Pax4 protein only in the pancreatic islet b-cells of
animals that received doxycycline. Of note, the intense green staining within the islet in the c-myc (2) doxycycline image is nonspeciﬁc. E: Glucose
tolerance tests were performed on control ST animals and Pax4 animals treated or not with doxycycline. F: Insulin tolerance tests were also
performed on the same animals. Data are expressed as means 6 SEM from 3–6 animals per group. (A high-quality digital representation of this
ﬁgure is available in the online issue.)
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levels of IL-1b a n dt ol e a dt oh u m a ni s l e tb-cell death (17).
Interestingly, IL-1b transcript levels were suppressed by
50% in islets isolated from Pax4-overexpressing animals.
In contrast, Pax4R129W mutant mice exhibited a twofold
increase in IL-1b transcript levels compared with control
untreated ST islets (Fig. 3B). A parallel modulation in
transcript levels of the IL-1b antagonist was observed in
both transgenic animal models, whereas expression lev-
els of the IL-1b receptor remained unaltered (Fig. 3B).
FIG. 2. Pax4-overexpressing animals are protected against STZ-induced hyperglycemia. A: A single high dose of STZ (200 mg/kg body wt) was
injected in control (ST) and Pax4 animals treated with doxycycline (dox) (groups A and B). Blood glucose levels were measured three times per
week for up to 58 days. All animals prior to STZ injection received doxycycline in drinking water for 1 month starting at weaning. For further
assessment of the protective role of Pax4, doxycycline was removed from the drinking water at day 27. Blood glucose levels were followed for 2
weeks before a second injection of STZ on day 41 was administered to group A (arrow) while group B received only the vehicle. B: Alternatively,
Pax4 animals maintained on doxycycline (group D) were challenged with a second high dose of STZ (arrow) and glycemia was monitored for an
extra 22 days. Group C animals were sustained on doxycycline without an STZ rechallenge. C: Pax4, Pax4R129W, and ST animals were injected
with STZ; glycemia was then monitored for 30 days. Data are expressed as the means 6 SEM from 3–9 animals per group. Statistical difference was
tested by the nonparametric Mann-Whitney test (signiﬁcance from P < 0.05). D: Immunohistochemical analysis of glucagon (green) and insulin
(red) on representative pancreatic parafﬁn sections from doxycycline-treated ST, Pax4, and Pax4R129W mice challenged or not with STZ. Animals
were killed on day 27, and parafﬁn sections were prepared from ST animals that received citrate buffer injection (a, d, g, and j) or challenged with
STZ (b, e, h, and k) and from Pax4 (c, f, i, and l) or Pax4R129W (c’,f ’,i ’, and l’) animals injected with STZ injection. Bars, 50 mm for a, d, g, and j and
25 mm for remaining panels. (A high-quality digital representation of this ﬁgure is available in the online issue.)
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Pax4-overexpressing islets treated with cytokines. A
hallmark of cytokine-mediated cell death is the activation of
the nuclear factor (NF)-kB pathway, which leads to en-
hanced NOS2 and COX2 expression and the downstream
increase in nitric oxide (NO) production, ultimately resulting
in cytochrome C release from mitochondria (18). Consistent
with this model, islets isolated from Pax4 mice and exposed
to cytokines in the absence of doxycycline exhibited a 2.5-
fold increase in cytochrome C release. In contrast, cyto-
chrome C release was abrogated in doxycycline-treated
Pax4 islets, whereas Pax4R129W-overexpressing islets dis-
played a threefold increase compared with noncytokine-
treated islets (Fig. 4A and B). Interestingly, NOS2 transcript
levels were only signiﬁcantly elevated in Pax4R129W islets,
whereas COX2 levels were augmented in both mutant and
wild-type Pax4 islets (Fig. 4C). Despite differences in NOS2
expression, both Pax4 and Pax4R129W islets presented
as i g n i ﬁcant increase in cytokine-induced nitrite production,
an indicator of NO production (Fig. 4D). However, Pax4
islets displayed a trend toward a small decrease in nitrite
production compared with non–doxycycline-treated islets.
Overexpression of Pax4 alters expression of MafA,
GLUT2, insulin, and Bcl2. To further delineate the mech-
anism by which Pax4 protects b-cells from either STZ- or
cytokine-induced apoptosis, we determined mRNA expres-
sion levels of key b-cell markers and those of antiapoptotic
genes in islets of Pax4- and Pax4R129W-overexpressing
animals (Fig. 5A). Transcript levels of Pdx1 and Pax6 were
not altered in Pax4- or Pax4R129W-overexpressing islets,
whereas MafA, GLUT2, and insulin levels were decreased
in both animal models. Immunohistochemistry conﬁrmed
decreased MafA and GLUT2 protein levels in islets of Pax4-
expressing mice (Fig. 5B and C). Bcl-2 but not Bcl-xL ex-
pression levels were increased threefold speciﬁcally in Pax4
islets compared with those in control animals without
doxycycline administration (Fig. 5A).
Because insulin and GLUT2 are target genes of MafA
(19,20) and because a Pax4 consensus sequence was pre-
dicted in region 3 of the MafA promoter (21), we in-
vestigated whether Pax4 could directly regulate MafA
transcription. Pax4 and Pax4R129W dose dependently
inhibited a luciferase reporter construct driven by region 3
of the MafA promoter, reaching 50% inhibition at the
highest dose (Fig. 5D). Repression was speciﬁc; Pax4 was
unable to inhibit the control pFOX-Luc construct. How-
ever, Pax4 failed to interact with the putative binding site
identiﬁed in this MafA region (MafAR3Pax4), whereas it
displayed speciﬁc binding to the G3 element of the gluca-
gon promoter (data not shown) (22).
FIG. 3. Isolated islets from Pax4 transgenic mice are protected against cytokine-induced apoptosis. A: Freshly isolated islets from ST animals and
double transgenic animals (Pax4, left panel, and Pax4R129W, right panel) were cultured with 1 mg/L doxycycline for 48 h and subsequently
challenged with a mix of IL-1b, g-interferon (INFg), and TNF-a. Cell death was measured using a cell death detection ELISA kit. Results are
expressed as means 6 SEM of three or four independent experiments relative to nontreated islets. B:I L - 1 b, IL-1Ra, and IL-1R1 mRNA expression
levels were measured by Q-RT-PCR in either Pax4- or PaxR129W-overexpressing animals. Relative mRNA levels were normalized to the transcript
levels of the housekeeping gene cyclophilin. Data were calculated as fold change compared with ST animals that received doxycycline (dashed line)
and expressed as means 6 SEM from 3–5 animals per group. Statistical difference was tested by one-way ANOVA with Bonferroni post hoc test.
*P < 0.05 and ***P < 0.001.
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induced hyperglycemia. STZ is selectively taken up by
b-cells through GLUT2 (23). Because GLUT2 levels were
decreased in Pax4-overexpressing islets, we determined
whether such inhibition would be sufﬁcient to protect
b-cells against STZ. To this end, the GLUT2 heterozygous
mouse model was used in order to directly measure the
impact of the glucose transporter in STZ-mediated cell
death. Transcript levels of the transporter were reduced by
60% in heterozygous GLUT2 mice (Fig. 6A). Similarly to
Pax4 mice, these animals were refractory to STZ-induced
b-cell apoptosis, whereas control wild-type littermates
were sensitive to the toxic agent (Fig. 6B). These results
suggest that the protective effect of Pax4 against STZ is
potentially partially conveyed by reduced GLUT2 expres-
sion. However, despite similarly lower levels of GLUT2,
Pax4R129W mice are only partially protected against STZ,
suggesting that alternative detrimental processes are as-
sociated with the mutant phenotype.
Transient overexpression of Pax4 improves total
pancreatic insulin content after 4 months. Adenoviral-
mediated overexpression of Pax4 in cultured rat islets was
shown to hamper insulin secretion (11). Although this ef-
fect was not observed in Pax4 transgenic animals treated
FIG. 4. Pax4 overexpression protects from cytokine-induced b-cell death by impeding mitochondrial cytochrome C release. A: Immunoﬂuorescent
localization of cytochrome C (green), TOM-20 (red), and DAPI (blue) within islet cells treated with or without cytokines in the presence or
absence of either Pax4 (□) or Pax4R129W (■) expression. B: Quantiﬁcation of cytochrome C release from the mitochondria. Metamorph software
was used to measure the area of red (TOM-20) and green (cytochrome C) ﬂuorescence. A total of 20 images, each containing 4–5 cells, were taken
per condition and per mouse in three independent experiments. Total green ﬂuorescence (cytochrome C) area was then divided by total red
ﬂuorescence (TOM-20) area. Values >1 indicate that cytochrome C is external to the mitochondria, and values £1 indicate that it is inside the
organelle. C: Q-RT-PCR analysis of nos2 and cox2 transcript levels in islets of Pax4 and Pax4R129W transgenic animals treated with doxycycline.
Relative mRNA levels were normalized to the transcript levels of the housekeeping gene cyclophilin. Data were calculated as fold change compared
with ST animals that received doxycycline (represented by dashed line) and expressed as the means 6 SEM from four animals per group. D: Nitrite
release in culture media was estimated using the Griess reagent. Data were expressed as means 6 SEM from three independent experiments.
Statistical difference was tested by one-way ANOVA with Bonferroni post hoc test. *P < 0.05, **P < 0.01, and ***P < 0.001. INFg, g-interferon.
(A high-quality digital representation of this ﬁgure is available in the online issue.)
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sponse to glucose were greatly reduced in animals treated
for 4 months (Fig. 7A). This was accompanied by glucose
intolerance in these animals (Fig. 7B). Furthermore,
morphological analysis of pancreas isolated from Pax4-
expressing mice revealed altered islet architecture typi-
ﬁed by an increased number of enlarged intercellular
spaces, reminiscent of capillaries detected in control islets
(Supplementary Fig. 3). To determine whether this effect
was reversible, we removed doxycycline from the drinking
water of 4-month–treated animals to repress Pax4 ex-
pression and reevaluated plasma insulin levels 1 month
later. Consistent with our premise, the rise in plasma in-
sulin levels in response to glucose was rescued in trans-
genic animals subsequent to removal of doxycycline (Fig.
7C). Total pancreatic insulin content was signiﬁcantly
increased in Pax4 mice after removal of doxycycline
(Fig. 7D).
Long-term (4 months) but not short-term (1 month)
Pax4 overexpression increases islet b-cell replication.
The increase in insulin content observed after doxycycline
removal (Fig. 7D) suggests that long-term expression of
Pax4 may induce b-cell replication. Consistent with this
premise, islets isolated from Pax4 mice that underwent
4-month but not 1-month doxycycline treatment showed
reduced glucose-induced plasma insulin levels (Fig. 7A)a n d
exhibited increased BrdU labeling of b-cells compared
with control ST islets (Fig. 8A). This was accompanied
by an overall nonsigniﬁcant increase in the proportion of
b-cells (Fig. 8B). A BrdU
+/insulin
2 cell subpopulation was
also detected speciﬁcally in Pax4-overexpressing islets (Fig.
8A). These cells were also negative for glucagon and
FIG. 5. Induction of Pax4 in islets suppresses MafA, insulin, and GLUT2 expression, whereas it increases Bcl-2. A: Q-RT-PCR was performed on
islets isolated from doxycycline-treated Pax4 and Pax4R129W animals. Relative mRNA levels were normalized to the transcript levels of the
housekeeping genes cyclophilin and/or rps29. Data were calculated as fold change compared with ST animals that received doxycycline (dashed
line) and are expressed as means 6 SEM from 4–5 animals per group. Statistical difference was tested by one-way ANOVA with Bonferroni post hoc
test (*P < 0.05, **P < 0.01, and ***P < 0.001). Immunohistochemistry analysis of MAFA (B) and GLUT2 (C) was performed on pancreatic sections
from Pax4-overexpressing animals and in control ST animals treated with doxycycline. D: Transient cotransfection studies using INS-1E cells were
performed with increasing amounts of either Pax4 or PaxR129W expression vectors (0.25, 0.50, 0.75, and 1 mg) along with 500 ng of either pFOX-
Luc or pFOX-MafAR3-Luc. Data are presented as fold change of basal luciferase activity and expressed as the means 6 SEM of three experiments
(*P < 0.05). (A high-quality digital representation of this ﬁgure is available in the online issue.)
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impedes insulin transcription (Fig. 5A), we reasoned that
these cells were likely b-cells with low levels of insulin.
Therefore, Pdx1 was used as an alternative b-cell marker.
Most BrdU
+ cells were also Pdx1
+, and the total percentage
of these cells was equivalent to the sum of the insulin
+ and
insulin
2 cell subpopulations that were BrdU
+ (compare Fig.
8A and C). Despite a signiﬁcant increase in overall pro-
liferation (Fig. 8C), we did not detect an increase in the total
population of Pdx1
+ cells (Fig. 8D)o ra ni n c r e a s ei ni s l e t
mass due to a low number of proliferating cells. Consistent
with increased long-term cell replication, c-myc and Cdk4
but not Cdk2 or -6 were increased in Pax4-overexpressing
islets (Fig. 8E).
DISCUSSION
Our study highlights the physiological role of Pax4 in vivo
as a regulator of mature islet b-cell survival and pro-
liferation. Pax4 prevented development of hyperglycemia
in animals exposed to environmental insults such as re-
peated STZ challenges and protected islets against cyto-
kine-mediated apoptosis. The diabetes-associated R129W
mutation was less efﬁcient in protecting animals against
STZ-induced hyperglycemia. The detrimental effect of the
mutation was only revealed in the presence of harmful
environmental cues highlighting the interplay between ge-
netic determinants and the environment in the development
of hyperglycemia (24). Thus, in response to physiological
demand or pathophysiological situations, Pax4 expression
may be transiently induced to protect and to compensate
b-cell mass, whereas the mutant variant would be unable to
achieve this, resulting in the gradual loss of b-cells and ul-
timately diabetes. The regulation of Pax4 expression by
environmental factors provides a likely explanation for the
failure of GWAS to identify Pax4 as a diabetic susceptibility
gene as well as for discrepancies in different studies to
validate the association of Pax4 polymorphisms with type 2
diabetes in various ethnic populations (7).
One mechanism by which Pax4, but not Pax4R129W,
protects b-cells against STZ- and cytokine-induced cell
death may, in part, be connected to the regulation of se-
lective target genes of the NF-kB signaling cascade (25).
Indeed, we found that transcript levels of IL-1b, the pre-
dominant cytokine implicated in the activation of the NF-
kB pathway, were decreased in Pax4-expressing islets,
whereas they were increased in Pax4R129W islets. Con-
sistent with NF-kB activation, transcript levels of its target
gene nos2 were selectively higher in mutant animals,
whereas levels of the target gene cox2 were increased in
both Pax4 and Pax4R129W. NOS2 is involved in NO pro-
duction and downstream stimulation of apoptosis (25),
whereas the COX2-generated metabolite prostaglandine E2
was found to be antiapoptotic (26). As IL-1b was shown to
autostimulate expression levels of endogenous IL-1b (17)
and to induce b-cell death in human islets (27), Pax4-
mediated inhibition of IL-1b transcription with a concomitant
increase in COX2 levels may confer increased resistance
to apoptosis. In contrast, elevated basal levels of IL-1b and
NOS2 in Pax4R129W-overexpressing mice may sensitize
islet cells to NO-induced apoptosis. Furthermore, because
NO can also be released from islets exposed to STZ (28),
we suggest that Pax4R129W mice are more prone to cell
death than GLUT2 heterozygous mice because of an
increased predisposition to NO-mediated apoptosis. In-
terestingly, the levels of the IL-1b antagonist, IL-1Ra, were
also increased in mutant islets, suggesting restoration of
an IL-1b–to–IL-1Ra ratio that prevents activation of the
apoptotic program (29). Consistent with this model, sev-
eral putative Pax4 binding sites were predicted in both the
il-1b and nos2 gene promoters.
Despite differences in Il-1b levels, both Pax4- and
Pax4R129W–expressing islets exhibited similar levels of
NO production upon exposure to cytokines. This indicates
that the NF-kB signaling pathway can still be fully acti-
vated upon strong exogenous stimulation and that the
protection conveyed by Pax4 is relayed through additional
gene product that blocks the NF-kB apoptotic pathway.
One such candidate gene could be Bcl-2, which regulates
the mitochondrial response to proapoptotic signals, pre-
venting the release of cytochrome C and the subsequent
activation of the cell death program (30). Indeed, we found
that Pax4- but not Pax4R129W-overexpressing islets ex-
hibited increased expression of Bcl-2 with blunted cytokine-
mediated cytochrome C translocation. Corroborating our
results, Bcl-2 overexpression was shown to protect mouse
and human islets against cytokine-induced apoptosis (31,32).
In contrast to our previous study in rat islets overex-
pressing Pax4 (11), the increased expression of Bcl-xL in
mouse islets was not detected, possibly as a result of spe-
cies differences.
Overexpression of either Pax4 or Pax4R129W markedly
perturbed expression of MafA and two of its target genes,
glut2 and insulin, which are key markers of mature
FIG. 6. GLUT2 heterozygous mice are protected against STZ-mediated
hyperglycemia. A: GLUT2 diabetes mRNA expression levels were mea-
sured by Q-RT-PCR in isolated islets from GLUT2
+/+ and GLUT2
+/2 mice.
Relative mRNA levels were normalized to the transcript levels of the
housekeeping gene cyclophilin. Data were calculated as fold change
compared with GLUT2
+/+ mice and expressed as means 6 SEM from
three animals per group. Statistical difference was tested by unpaired
t test (***P < 0.001). B: GLUT2
+/+ and GLUT2
+/2 male mice were injected
with a single dose of STZ (200 mg/kg body wt), and glycemia was moni-
tored for up to 7 days. Data are expressed as means 6 SEM from three
animals per group. Statistical difference was tested by the nonparametric
Mann-Whitney test.
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tivity of a luciferase construct harboring the MafA gene
promoter region 3, we could not detect Pax4 binding to
a putative binding site within this region. Preliminary ChIP
assay results revealed no convincing interaction of Pax4
with region 3, suggesting an indirect effect of Pax4 on
MafA expression. However, we have previously demon-
strated that Pax4 impairs glucagon and insulin gene tran-
scriptions through direct protein interaction with Pax6
(22). Given that Pax6 was recently shown to bind to the
mafa gene promoter and to regulate transcription (33), we
speculate that Pax4 may be inhibiting MafA expression by
a mechanism similar to the one delineated for glucagon
and insulin. Inhibition through protein-protein interaction,
and not direct DNA binding activity, would explain the
inhibitory effect observed with the weaker DNA-interacting
mutant variant.
Long-term overexpression of Pax4 resulted in a blunted
glucose-induced rise in plasma insulin levels—an effect
reversible upon inhibition of Pax4. A recent study also
reported impaired glucose-induced insulin secretion in
an animal model in which Pax4 was constitutively
overexpressed in a-cells. These cells were converted to
b-cells that remained functional for up to 4 weeks before
an unexpected decline in insulin secretion occurred. Ani-
mals ultimately died of hyperglycemia (8). We would
therefore like to propose that Pax4-dependent impaired
insulin secretion is mediated by the long-term repression
of the mature b-cell marker MafA and insulin.
Aberrant expression of Pax genes were shown to con-
vert cells to a less differentiated state and to promote self-
renewal and increasing survival (34). Consistent with this
premise, a subpopulation of replicating Pdx1
+/insulin
2 cells
was identiﬁed in Pax4-overexpressing islets. These cells
were also negative for both glucagon and somatostatin,
suggesting that they likely represent insulin-deprived b-cells
resulting from repression of MafA and insulin transcription
by Pax4. A similar b-cell subpopulation was recently char-
acterized in vitro (35). These cells displayed impaired
glucose-induced insulin secretion and were prone to pro-
liferation in response to activin A (36). More importantly,
MafA and GLUT2 transcript levels were lower in this sub-
population, whereas Pax4 levels were higher. Taken to-
gether, these results suggest that Pax4 under physiological
FIG. 7. Transient overexpression of Pax4 improves glucose tolerance and total pancreatic insulin content after 4 months. A: Plasma insulin levels,
measured 15 min after an injection of 2 g glucose/kg body wt in Pax4-overexpressing animals and in ST animals that were maintained on doxy-
cycline (Dox) for 4 months. B: Glucose tolerance tests were performed in the same animals (Pax4-overexpressing [●] and ST [□] animals that were
maintained on doxycycline for 4 months). C: After doxycycline treatment was abolished for 1 month, plasma insulin levels were reevaluated as in
A. D: Total pancreatic insulin content was measured as indicated in RESEARCH DESIGN AND METHODS in Pax4 animals that received doxycycline for
4 months and then were not treated for 1 month. Data are expressed as means 6 SEM from ﬁve animals per group. Statistical difference was tested
by t test (*P < 0.05).
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b-like cells prone to proliferation. Substantiating this hy-
pothesis, Cdk4 and c-myc transcript levels were increased
in Pax4-overexpressing islets. Adenovirus-mediated Cdk4
expression was shown to increase mouse islet cell pro-
liferation (37), whereas its repression causes insulin de-
ﬁciency and hyperglycemia (38). Similarly, b-cell–speciﬁc
overexpression of c-myc caused downregulation of insulin
gene expression with a concomitant increase in pro-
liferation and apoptosis (39). That a fraction of islet b-cells
responds to proliferation would provide a mechanism by
which a pool of mature cells can rapidly undergo regulated
replication to compensate for lost cells while quiescent
cells retain the ability to regulate blood glucose.
In summary, in vivo overexpression of Pax4 reveals an
important role of the transcription factor in islet b-cell
proliferation and survival. The detrimental impact of Pax4
mutations is only revealed upon environmental stresses,
which reinforces the critical role of gene-environment in-
teraction in the development of diabetes.
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